20 May 2025 • In a study of T2DM patients, intravenous infusion of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) (50–100×10⁶ cells) led to significant HbA1c reductions at 6 months and 12 months, along with decreased insulin and insulin resistance.

Liver enzymes (ALT, GGT), hs-CRP, and renal function (eGFR, creatinine) improved, especially in early-stage CKD. Hormonal shifts included increased testosterone in men and estradiol in women. No adverse events were reported.

UC-MSCs appear to be a safe, effective adjunct for improving glycemic control and reducing inflammation in T2DM.

Source: Dovepress | Read Full Story